Stocktube video
01/05/2014

Silence Therapeutics morphing into commercial drug company

View full size
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: SLN
Latest Price: 214.38p  (-1.43% Descending)
52-week High: 388.75p
52-week Low: 185.00p
Market Cap: 111.48M
1 year chart More charts
Deal SLN Tax Free*
*subject to change and depends on individual circumstances.
1 day chart More charts
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Silence Therapeutics
www.silence-therapeutics.com
Deal Silence Therapeutics Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.

Silence Therapeutics plc (LSE: SLN) is a global leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases.

The company possesses one of the world’s most comprehensive RNAi therapeutic platforms comprised of proprietary delivery technologies, potent siRNA...

Read more
Pdf

Silence Therapeutics promotes Sedgwick to CEO role; Christély resigns

February 10 2012, 7:29am The company develops siRNAs, which are double-stranded molecules that silence certain genes. These are being developed to be used in targeting multiple disease types, including cancer

Gene silencing specialist Silence Therapeutics (LON:SLN) announced today that Tony Sedgwick has been appointed the new CEO of the company following the resignation of Thomas Christély.

Sedgwick was formerly the chief business officer and his promotion takes effect immediately, the firm said.

Christély has resigned as a director for personal reasons but will ensure a smooth transition, the company added.

The company's chairman Jerry Randall said: "Tony has a great deal of relevant experience gained from the global pharmaceutical industry. He has made a very positive impact on Silence since joining in September last year and has demonstrated the right leadership skills needed as the company continues to gain momentum."

He thanked Christély for his many years of valuable service, on behalf of the board, and wished him well for the future.

New chief executive Sedgwick said that since joining the company, he had been excited about the opportunities ahead.

"We have already strengthened the business development team with the appointment of Dr Georg Buchner who will now take full responsibility for business development.

"The company's pipeline including Atu027 is making good progress and is endorsed by external partners," he said.

He added that in the next few years, he planned to increase the commercial focus of the company.

The company develops siRNAs, which are double-stranded molecules that silence certain genes. These are being developed to be used in targeting multiple disease types, including cancer.

Last month, the company announced a collaboration agreement with
US–based firm miRagen to assess delivery methods for new, micro versions of gene silencing technology to treat serious diseases.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.